Dr Lal PathLabs will acquire a 70% controlling interest in Gujarat-based SN Genelab for ₹168 crore to expand its genomics diagnostic capabilities. The deal includes a performance-linked payout of ₹31.5 crore and is expected to close by November 2026. This move helps the company strengthen its portfolio in the higher-value specialized testing segment.
Dr Lal PathLabs has announced a deal to acquire a 70% controlling stake in SN Genelab for ₹168 crore. The Gujarat-based diagnostics firm specialises in genomics, a field that involves advanced testing which often commands higher profit margins compared to routine pathology tests. The acquisition is set to close by November 30, 2026, and will see the company become a subsidiary of the Delhi-headquartered diagnostic chain.
Expanding Genomics Footprint
The investment is part of Dr Lal PathLabs' broader strategy to capture a larger share of the specialized and wellness-oriented diagnostic market. By integrating SN Genelab’s genomics expertise, the company aims to strengthen its competitive position in a sector where players like Metropolis Healthcare and other regional diagnostic chains are also aggressively expanding. For investors, this acquisition marks a pivot toward capturing higher-value services, which can help defend the company’s profit margins against the price competition often seen in routine testing.
Financials and Deal Structure
The transaction is valued at approximately ₹168 crore for the 70% stake. Additionally, the company has structured an earn-out clause of ₹31.5 crore, which is tied to specific performance targets. This ensures that the payout to the sellers is aligned with future growth, protecting the company from overpayment if the target entity’s performance does not meet expectations. SN Genelab has reported steady revenue growth, with turnover reaching ₹57.96 crore in the financial year ending 2026, rising from ₹53.36 crore in 2025 and ₹43.27 crore in 2024.
While the deal promises to broaden service offerings, the success of the investment will depend on how effectively Dr Lal PathLabs integrates the new entity into its existing network. Challenges in diagnostic acquisitions typically include retaining key scientific talent, maintaining testing accuracy standards, and scaling operations across a wider geography. Investors should watch for updates on the integration timeline and whether the genomics business achieves the expected growth to justify the acquisition cost. The company does not require regulatory approvals for this deal, as it is structured to fall outside related-party transactions, which should simplify the path to completion.